Galactoside Inhibitors with C3 Substitution for Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing galectin inhibitors are susceptible to hydrolytic and enzymatic degradation, are hydrophilic, and have poor absorption from the gastrointestinal tract, limiting their effectiveness as pharmaceutical agents.
Innovation Solution
Development of novel α-D-galactopyranose compounds with specific substitutions at the C3 position, such as thiophene triazole or fluorine substitutions, which enhance affinity and stability for galectin-1 and galectin-3, allowing for improved systemic uptake and oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural saccharides are used as galectin inhibitors, then binding affinity is achieved, but susceptibility to hydrolytic and enzymatic degradation increases
Solution Approach 1:
The patent modifies the chemical structure of natural saccharides by changing parameters such as introducing aromatic rings, heteroatoms, and specific functional groups at defined positions (e.g., C3 position substitutions). This transforms the inhibitor from a simple saccharide to a complex molecule with enhanced stability while maintaining galectin binding affinity through preserved carbohydrate recognition domain interactions.
Solution Approach 2:
The invention creates composite molecular structures combining saccharide moieties with stable aromatic and heterocyclic frameworks. These composite inhibitors integrate the binding capability of natural sugars with the stability of synthetic organic compounds, achieving both high affinity and resistance to degradation through synergistic structural design.
2Reliability
If natural saccharides are used as galectin inhibitors, then binding affinity is achieved, but absorption from the gastrointestinal tract deteriorates
Solution Approach 1:
The patent systematically modifies physical and chemical parameters of the inhibitor molecules, including introducing lipophilic aromatic groups and optimizing molecular weight and structural features. These parameter changes enhance membrane permeability and gastrointestinal absorption while preserving the essential carbohydrate binding function through carefully designed saccharide moieties.
3Ease of manufacture
If simple saccharide structures are used, then ease of synthesis is maintained, but stability and absorption deteriorate
Solution Approach 1:
The patent divides the inhibitor molecule into distinct functional segments: a stable aromatic or heterocyclic core providing structural integrity and resistance to degradation, and attached saccharide moieties providing galectin binding affinity. This segmentation allows each component to be optimized independently for its specific function while maintaining overall synthesizability through modular assembly approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel α-D-galactopyranose compounds demonstrate high affinity for galectin-1 and galectin-3, with improved stability and absorption, making them suitable for oral treatment of diseases and disorders.
Implementation Method 1
Galectins are proteins with a characteristic carbohydrate recognition domain (CRD) with a β-galactose binding site
Data Source
AI summary
The present invention relates to a D-galactopyranose compound of formula (1)whereinthe pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.